
GI Innovation wins US patent for dual-action IL-2 therapy targeting cold tumors
GI Innovation has secured U.S. patent protection for GI-108, its fourth-generation immunocytokine that targets CD73-driven tumors, where adenosine buildup suppresses immune responses and undercuts immunotherapy. The company said Wednesday it received a …